Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 3 September 2004:
Vol. 305. no. 5689, pp. 1466 - 1470
DOI: 10.1126/science.1099191
Prev | Table of Contents | Next

Reports

Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix

Loren D. Walensky,1,2 Andrew L. Kung,2,3 Iris Escher,4 Thomas J. Malia,5,6 Scott Barbuto,1 Renee D. Wright,3 Gerhard Wagner,5 Gregory L. Verdine,4* Stanley J. Korsmeyer1*

BCL-2 family proteins constitute a critical control point for the regulation of apoptosis. Protein interaction between BCL-2 members is a prominent mechanism of control and is mediated through the amphipathic {alpha}-helical BH3 segment, an essential death domain. We used a chemical strategy, termed hydrocarbon stapling, to generate BH3 peptides with improved pharmacologic properties. The stapled peptides, called "stabilized alpha-helix of BCL-2 domains" (SAHBs), proved to be helical, protease-resistant, and cell-permeable molecules that bound with increased affinity to multidomain BCL-2 member pockets. A SAHB of the BH3 domain from the BID protein specifically activated the apoptotic pathway to kill leukemia cells. In addition, SAHB effectively inhibited the growth of human leukemia xenografts in vivo. Hydrocarbon stapling of native peptides may provide a useful strategy for experimental and therapeutic modulation of protein-protein interactions in many signaling pathways.

1 Howard Hughes Medical Institute,
2 Department of Pediatric Hematology/Oncology and Children's Hospital Boston
3 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
4 Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
5 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
6 Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

* To whom correspondence should be addressed. E-mail: stanley_korsmeyer{at}dfci.harvard.edu (S.J.K.) and verdine{at}chemistry.harvard.edu (G.L.V.)

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Novel Bcl-2 Homology-3 Domain-like Sequences Identified from Screening Randomized Peptide Libraries for Inhibitors of the Pro-survival Bcl-2 Proteins.
E. F. Lee, A. Fedorova, K. Zobel, M. J. Boyle, H. Yang, M. A. Perugini, P. M. Colman, D. C. S. Huang, K. Deshayes, and W. D. Fairlie (2009)
J. Biol. Chem. 284, 31315-31326
   Abstract »    Full Text »    PDF »
Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis.
H. Dai, X. W. Meng, S.-H. Lee, P. A. Schneider, and S. H. Kaufmann (2009)
J. Biol. Chem. 284, 18311-18322
   Abstract »    Full Text »    PDF »
Molecular Basis for Bcl-2 Homology 3 Domain Recognition in the Bcl-2 Protein Family: IDENTIFICATION OF CONSERVED HOT SPOT INTERACTIONS.
G. Moroy, E. Martin, A. Dejaegere, and R. H. Stote (2009)
J. Biol. Chem. 284, 17499-17511
   Abstract »    Full Text »    PDF »
Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20.
K. Izumi, E. Kodama, K. Shimura, Y. Sakagami, K. Watanabe, S. Ito, T. Watabe, Y. Terakawa, H. Nishikawa, S. G. Sarafianos, et al. (2009)
J. Biol. Chem. 284, 4914-4920
   Abstract »    Full Text »    PDF »
Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents.
B. D. Zeitlin, I. J. Zeitlin, and J. E. Nor (2008)
J. Clin. Oncol. 26, 4180-4188
   Abstract »    Full Text »    PDF »
Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers.
F. A. Sinicrope, R. L. Rego, N. R. Foster, S. N. Thibodeau, S. R. Alberts, H. E. Windschitl, and D. J. Sargent (2008)
Clin. Cancer Res. 14, 4128-4133
   Abstract »    Full Text »    PDF »
Multimodal Targeting of the BCL-2 Family in Cancer.
L. D Walensky (2008)
Am. Assoc. Cancer Res. Educ. Book 2008, 349-356
   Abstract »    Full Text »    PDF »
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
L. T. Lam, G. Wright, R. E. Davis, G. Lenz, P. Farinha, L. Dang, J. W. Chan, A. Rosenwald, R. D. Gascoyne, and L. M. Staudt (2008)
Blood 111, 3701-3713
   Abstract »    Full Text »    PDF »
Anti-Apoptosis Mechanisms in Malignant Gliomas.
D. S. Ziegler, A. L. Kung, and M. W. Kieran (2008)
J. Clin. Oncol. 26, 493-500
   Abstract »    Full Text »    PDF »
BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death.
N. N. Danial (2007)
Clin. Cancer Res. 13, 7254-7263
   Abstract »    Full Text »    PDF »
The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family Members.
G. L. Verdine and L. D. Walensky (2007)
Clin. Cancer Res. 13, 7264-7270
   Abstract »    Full Text »    PDF »
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
M. Nguyen, R. C. Marcellus, A. Roulston, M. Watson, L. Serfass, S. R. Murthy Madiraju, D. Goulet, J. Viallet, L. Belec, X. Billot, et al. (2007)
PNAS 104, 19512-19517
   Abstract »    Full Text »    PDF »
The role of peptide motifs in the evolution of a protein network.
H. Saito, S. Kashida, T. Inoue, and K. Shiba (2007)
Nucleic Acids Res. 35, 6357-6366
   Abstract »    Full Text »    PDF »
The tail-anchoring domain of Bfl1 and HCCS1 targets mitochondrial membrane permeability to induce apoptosis.
J.-K. Ko, K.-H. Choi, Z. Pan, P. Lin, N. Weisleder, C.-W. Kim, and J. Ma (2007)
J. Cell Sci. 120, 2912-2923
   Abstract »    Full Text »    PDF »
Amphipathic Peptide-Based Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate Cancer Cells.
K. Rege, S. J. Patel, Z. Megeed, and M. L. Yarmush (2007)
Cancer Res. 67, 6368-6375
   Abstract »    Full Text »    PDF »
2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition.
P. S. Schwartz, M. K. Manion, C. B. Emerson, J. S. Fry, C. M. Schulz, I. R. Sweet, and D. M. Hockenbery (2007)
Mol. Cancer Ther. 6, 2073-2080
   Abstract »    Full Text »    PDF »
Targeting Multiple Arms of the Apoptotic Regulatory Machinery.
Y. Dai and S. Grant (2007)
Cancer Res. 67, 2908-2911
   Abstract »    Full Text »    PDF »
Mcl-1 Down-regulation Potentiates ABT-737 Lethality by Cooperatively Inducing Bak Activation and Bax Translocation.
S. Chen, Y. Dai, H. Harada, P. Dent, and S. Grant (2007)
Cancer Res. 67, 782-791
   Abstract »    Full Text »    PDF »
BCL2 Is a Downstream Effector of MIZ-1 Essential for Blocking c-MYC-induced Apoptosis.
J. H. Patel and S. B. McMahon (2007)
J. Biol. Chem. 282, 5-13
   Abstract »    Full Text »    PDF »
Mitochondrial Membrane Permeabilization in Cell Death.
G. Kroemer, L. Galluzzi, and C. Brenner (2007)
Physiol Rev 87, 99-163
   Abstract »    Full Text »    PDF »
A Membrane-targeted BID BCL-2 Homology 3 Peptide Is Sufficient for High Potency Activation of BAX in Vitro.
K. J. Oh, S. Barbuto, K. Pitter, J. Morash, L. D. Walensky, and S. J. Korsmeyer (2006)
J. Biol. Chem. 281, 36999-37008
   Abstract »    Full Text »    PDF »
A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo..
A. R. Shoemaker, A. Oleksijew, J. Bauch, B. A. Belli, T. Borre, M. Bruncko, T. Deckwirth, D. J. Frost, K. Jarvis, M. K. Joseph, et al. (2006)
Cancer Res. 66, 8731-8739
   Abstract »    Full Text »    PDF »
Targeting protein-protein interactions by rational design: mimicry of protein surfaces.
S. Fletcher and A. D Hamilton (2006)
J R Soc Interface 3, 215-233
   Abstract »    Full Text »    PDF »
Chemotherapeutic approaches for targeting cell death pathways..
M. S. Ricci and W.-X. Zong (2006)
Oncologist 11, 342-357
   Abstract »    Full Text »    PDF »
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.
R. Piva, R. Chiarle, A. D. Manazza, R. Taulli, W. Simmons, C. Ambrogio, V. D'Escamard, E. Pellegrino, C. Ponzetto, G. Palestro, et al. (2006)
Blood 107, 689-697
   Abstract »    Full Text »    PDF »
Messenger Molecules and Cell Death: Therapeutic Implications.
T. W. Sedlak and S. H. Snyder (2006)
JAMA 295, 81-89
   Abstract »    Full Text »    PDF »
Combination Bcl-2 Antisense and Radiation Therapy for Nasopharyngeal Cancer.
K. W. Yip, J. D. Mocanu, P.Y. B. Au, G. T. Sleep, D. Huang, P. Busson, W.-C. Yeh, R. Gilbert, B. O'Sullivan, P. Gullane, et al. (2005)
Clin. Cancer Res. 11, 8131-8144
   Abstract »    Full Text »    PDF »
Oncogenes as molecular targets in lymphoma.
A. Hachem and R. B. Gartenhaus (2005)
Blood 106, 1911-1923
   Full Text »    PDF »
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach.
J. S. Abramson and M. A. Shipp (2005)
Blood 106, 1164-1174
   Abstract »    Full Text »    PDF »
Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease.
O. Takeuchi, J. Fisher, H. Suh, H. Harada, B. A. Malynn, and S. J. Korsmeyer (2005)
PNAS 102, 11272-11277
   Abstract »    Full Text »    PDF »
New Approaches and Therapeutics Targeting Apoptosis in Disease.
U. Fischer and K. Schulze-Osthoff (2005)
Pharmacol. Rev. 57, 187-215
   Abstract »    Full Text »    PDF »
Solution Structure of Prosurvival Mcl-1 and Characterization of Its Binding by Proapoptotic BH3-only Ligands.
C. L. Day, L. Chen, S. J. Richardson, P. J. Harrison, D. C. S. Huang, and M. G. Hinds (2005)
J. Biol. Chem. 280, 4738-4744
   Abstract »    Full Text »    PDF »
2004: Signaling Breakthroughs of the Year.
E. M. Adler, N. R. Gough, and L. B. Ray (2005)
Sci. STKE 2005, eg1
   Abstract »    Full Text »    PDF »
Subversion of the Bcl-2 Life/Death Switch in Cancer Development and Therapy.
J.M. ADAMS, D.C.S. HUANG, A. STRASSER, S. WILLIS, L. CHEN, A. WEI, M. VAN DELFT, J.I. FLETCHER, H. PUTHALAKATH, J. KURODA, et al. (2005)
Cold Spring Harb Symp Quant Biol 70, 469-477
   Abstract »    PDF »
Modulating the Bcl-2 Family of Apoptosis Suppressors for Potential Therapeutic Benefit in Cancer.
G. C. Shore and J. Viallet (2005)
Hematology 2005, 226-230
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)